MILFORD, Mass., Feb 11, 2011 /PRNewswire/ -- SeraCare Life Sciences, Inc. (Nasdaq: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its first quarter of fiscal year 2011, ended December 31, 2010.
"In the first quarter of fiscal 2011 we took important steps to position ourselves to achieve our long-term strategic goal of doubling SeraCare's revenues during the next three to four years. As we stated during our previous earnings conference call, we anticipated a moderation in our revenues during the first half of fiscal 2011 as we implement comprehensive sales force improvements and completed our work under a significant services contract," commented Susan Vogt, President and Chief Executive Officer of SeraCare. "Additionally, we are in the final stages of converting a key customer to a new, jointly developed, custom-manufactured bulk product. This transition has resulted in some short term disruption in their ordering, but we believe will ultimately enhance our long term relationship. We believe that the completion of these initiatives will yield a positive revenue uptick and improved operating performance in the second half of the fiscal year."
SeraCare reported revenue of $10.5 million for the quarter ended December 31, 2010 compared to $11.3 million for the same quarter of the prior year, reflecting a 7% decrease. Gross margins decreased to 38% for the quarter compared to 44% for the same quarter of the prior year. The Company earned net income of $1.6 million, which included a non-recurring reorganization benefit of $0.8 million, and earnings per share on a basic and diluted basis of $0.08 for the quarter ended December 31, 2010 compared to net income of $1.3 million and earnings per share of $0
|SOURCE SeraCare Life Sciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved